Trial reportBMC pulmonary medicine2026
A pilot randomised, open label controlled trial comparing safety and efficacy of pleural irrigation with normal saline versus intrapleural tissue plasminogen activator and DNase (fibrinolytic therapy) in pleural infection.
Trial report in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05903417 (A Randomised Open-Label Controlled Trial of Pleural Irrigation With Normal Saline Versus Intrapleural Tissue Plasminogen Activator and DNase), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised Open-Label Controlled Trial of Pleural Irrigation With Normal Saline Versus Intrapleural Tissue Plasminogen Activator and DNase (Fibrinolytic Therapy) in Pleural Infection.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundManagement of pleural infection included adjunctive intrapleural fibrinolytic therapy (IPFT) using alteplase and Deoxyribonuclease (DNase) and saline irrigation. This study compared the safety and efficacy of IPFT versus saline irrigation.
methodsThis open-label, randomized trial allocated patients to receive IPFT (5 mg alteplase with 5 mg DNase) or saline irrigation (250 milliliters three times daily for 3 days). The primary outcome was a safety comparison between the two arms. Secondary outcomes included pleural fluid drainage, radiographic clearance, inflammatory markers resolution, length of hospitalization, treatment success, and mortality at 30 days.
resultsForty subjects were randomized. Safety outcomes were similar, with no adverse events observed. Two patients in the saline arm failed therapy at day 7 and required crossover to IPFT. Both groups demonstrated substantial pleural drainage and biochemical improvement, with greater but non-significant radiological clearance in the IPFT group. At day 7, treatment success was 100% in the IPFT group [intention to treat (ITT) 20/20; per-protocol (PP) 20/20] and 90% in the saline group (ITT 18/20; PP 18/20). By day 30, success was 100% in both groups (IPFT, ITT 20/20; PP 19/19; saline, ITT 20/20; PP 18/18). Mortality occurred in one IPFT patient (2.5%), attributed to unrelated aspiration pneumonia.
conclusionIPFT and intrapleural saline irrigation are safe and effective adjuncts in pleural infection management, with comparable short-term outcomes. In centres where IPFT is unavailable, saline irrigation may be a reasonable alternative. Larger multicentre trials are needed to confirm these findings. The study was registered with Clinical Trials number (NCT05903417) on 15.06.2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.